Literature DB >> 22936053

Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: a study of a Brazilian cohort.

Melissa de Freitas Cordeiro-Silva1, Elaine Stur, Lidiane Pignaton Agostini, José Roberto Vasconcelos de Podestá, José Carlos de Oliveira, Mariana Silveira Soares, Elismauro Francisco Mendonça, Sônia Alves Gouvea, Sandra Ventorin Von Zeidler, Iúri Drumond Louro.   

Abstract

Epigenetic silencing of cancer-related genes plays an important role in oral/oropharyngeal squamous cell carcinoma (OSCC). We evaluated promoter hypermethylation of 4 cancer-related genes in OSCCs of a Brazilian cohort and determined its relationship with exposure to alcohol, tobacco, HPV infection and clinicopathological parameters. CDKN2A (cyclin-dependent kinase inhibitor 2A or p16), SFN (stratifin or 14-3-3 σ), EDNRB (endothelin receptor B) and RUNX3 (runt-related transcript factor-3) had their methylation patterns evaluated by MSP analysis in OSCC tumors (n = 45). HPV detection was carried out by PCR/RFLP. Aberrant methylation was detected in 44/45 (97.8 %) OSCC; 24.4 % at CDKN2A, 77.8 % at EDNRB, 17.8 % at RUNX3 and 97.8 % at SFN gene. There was no significant association between methylation patterns and clinical parameters. HPV (subtype 16) was detected in 3 out of 45 patients (6 %). Our findings indicate that HPV infection is uncommon and methylation is frequent in Brazilian OSCCs, however, EDNRB and SFN gene methylation are not suitable OSCC biomarkers due to indistinct methylation in tumoral and normal samples. In contrast, CDKN2A and RUNX3 genes could be considered differentially methylated genes and potential tumor markers in OSCCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936053     DOI: 10.1007/s11033-012-1885-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  30 in total

1.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

Review 2.  Oral squamous cell carcinoma overview.

Authors:  Crispian Scully; Jose Bagan
Journal:  Oral Oncol       Date:  2009-02-26       Impact factor: 5.337

3.  The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells.

Authors:  M M Pao; M Tsutsumi; G Liang; E Uzvolgyi; F A Gonzales; P A Jones
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

4.  Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women.

Authors:  Sarah M Leonard; Wenbin Wei; Stuart I Collins; Merlin Pereira; Afaf Diyaf; Christothea Constandinou-Williams; Lawrence S Young; Sally Roberts; Ciarán B Woodman
Journal:  Carcinogenesis       Date:  2012-05-02       Impact factor: 4.944

5.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.

Authors:  A T Ferguson; E Evron; C B Umbricht; T K Pandita; T A Chan; H Hermeking; J R Marks; A R Lambers; P A Futreal; M R Stampfer; S Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

Authors:  Wun-Jae Kim; Eun-Jung Kim; Pildu Jeong; Changyi Quan; Jiyeon Kim; Qing-Lin Li; Jeong-Ook Yang; Yoshiaki Ito; Suk-Chul Bae
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma.

Authors:  Tai Young Kim; Hyeon Joo Lee; Kyu Sang Hwang; Minjin Lee; Jae Won Kim; Yung-Jue Bang; Gyeong Hoon Kang
Journal:  Lab Invest       Date:  2004-04       Impact factor: 5.662

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma.

Authors:  Carmen J Marsit; Marshall R Posner; Michal D McClean; Karl T Kelsey
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection.

Authors:  Priscilla D Negraes; Francine P Favaro; João Lauro V Camargo; Maria Luiza C S Oliveira; José Goldberg; Cláudia A Rainho; Daisy M F Salvadori
Journal:  BMC Cancer       Date:  2008-08-14       Impact factor: 4.430

View more
  13 in total

Review 1.  Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review.

Authors:  Pauline M W van Kempen; Rob Noorlag; Weibel W Braunius; Inge Stegeman; Stefan M Willems; Wilko Grolman
Journal:  Epigenetics       Date:  2013-10-29       Impact factor: 4.528

2.  Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis.

Authors:  Yali Liang; Lianping He; Hui Yuan; Yuelong Jin; Yingshui Yao
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

3.  Secreted frizzled‑related protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma.

Authors:  Can Xiao; Lili Wang; Lifang Zhu; Chenping Zhang; Jianhua Zhou
Journal:  Mol Med Rep       Date:  2014-09-05       Impact factor: 2.952

4.  Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome.

Authors:  Annette M Lim; Ida Lm Candiloro; Nicholas Wong; Marnie Collins; Hongdo Do; Elena A Takano; Christopher Angel; Richard J Young; June Corry; David Wiesenfeld; Stephen Kleid; Elizabeth Sigston; Bernard Lyons; Danny Rischin; Benjamin Solomon; Alexander Dobrovic
Journal:  Clin Epigenetics       Date:  2014-12-09       Impact factor: 6.551

5.  Prognostic factors in oral and oropharyngeal cancer based on ultrastructural analysis and DNA methylation of the tumor and surgical margin.

Authors:  Daniela Mielcarek-Kuchta; Jarosław Paluszczak; Monika Seget; Katarzyna Kiwerska; Wiesława Biczysko; Krzysztof Szyfter; Witold Szyfter
Journal:  Tumour Biol       Date:  2014-05-01

Review 6.  Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors.

Authors:  Paolo Boscolo-Rizzo; Carlo Furlan; Valentina Lupato; Jerry Polesel; Elisabetta Fratta
Journal:  Clin Epigenetics       Date:  2017-11-28       Impact factor: 6.551

7.  Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus.

Authors:  Christopher G Németh; Christoph Röcken; Reiner Siebert; Jörg Wiltfang; Ole Ammerpohl; Volker Gassling
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

8.  Promoter Hypermethylation of Tumor-Suppressor Genes p16INK4a, RASSF1A, TIMP3, and PCQAP/MED15 in Salivary DNA as a Quadruple Biomarker Panel for Early Detection of Oral and Oropharyngeal Cancers.

Authors:  Chamikara Liyanage; Asanga Wathupola; Sanjayan Muraleetharan; Kanthi Perera; Chamindie Punyadeera; Preethi Udagama
Journal:  Biomolecules       Date:  2019-04-12

9.  The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival.

Authors:  Jarosław Paluszczak; Joanna Sarbak; Magdalena Kostrzewska-Poczekaj; Katarzyna Kiwerska; Małgorzata Jarmuż-Szymczak; Reidar Grenman; Daniela Mielcarek-Kuchta; Wanda Baer-Dubowska
Journal:  Tumour Biol       Date:  2014-12-07

Review 10.  p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review.

Authors:  A Al-Kaabi; L W van Bockel; A J Pothen; S M Willems
Journal:  Dis Markers       Date:  2014-04-07       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.